RxDoctor Payments Data

Jorida Lulaj, NP

Family · Scottsdale, AZNPI 1679973911

Payments from drug & device makers

$2,098in general payments, 2019–2025

Across 110 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$289
  • Electromed, Inc.$256
  • Pulmonx Corporation$176
  • Regeneron Healthcare Solutions, Inc.$176
  • United Therapeutics Corporation$140
  • Takeda Pharmaceuticals U.S.A., Inc.$130
  • plus $932 from 23 others

What the payments were for

  • Food & beverage$2,02697%
  • Education$723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,098 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$17,113
Medicare patients
112
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$44,554
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr48$30,199
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$26,816
Spiriva RespimatTiotropium Bromide33$24,441
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$20,133
EliquisApixaban12$9,328
BreynaBudesonide/Formoterol Fumarate12$3,708
SymbicortBudesonide/Formoterol Fumarate13$3,027
Albuterol Sulfate HfaAlbuterol Sulfate99$2,650
Azithromycin55$359
Prednisone75$309
Methylprednisolone21$165
Montelukast Sodium12$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$51$74,75394 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$108$51,25881 claims
AstraZenecaBreztri Aerosphere, Symbicort$289$23,15941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →